查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401866

到 2030 年毒蕈碱乙酰胆碱受体的全球市场预测：按类型、产品、配销通路、应用、最终用户和地区进行分析

Muscarinic Acetylcholine Receptor Market Forecasts to 2030 - Global Analysis By Type (M1, M4, M5 and Other Types), Product (Tropicamide, Nu-0467154, Anauex-273 and Other Products), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球毒蕈碱乙酰胆碱受体市场规模为 17.5 亿美元，预计在预测期内复合年增长率为 6.9%，到 2030 年将达到 27.9 亿美元。

毒蕈碱乙酰胆碱受体是一类可以抑制突触后神经元并参与多种週边和中枢活动的控制的受体。它负责调节副交感神经系统的生理后果。它具有抑制和兴奋作用，可以阻断或刺激反应，并作为胆碱能神经元储存在产生乙酰胆碱的神经元中。

据支持医学研究的美国非营利组织美国心臟协会称，到 2060 年，美国患有阿兹海默症和相关失智症的人数预计将增加到 930 万人。

神经系统疾病盛行率增加

由于人口高龄化和生活方式的改变，阿兹海默症、帕金森氏症和思觉失调症等神经系统疾病变得越来越普遍。毒蕈碱乙酰胆碱受体在这些疾病中发挥重要作用，并且是药物开发的有吸引力的标靶。此外，由于迫切需要解决医疗保健系统中神经系统疾病的负担以及对创新治疗方法的需求不断增长，市场正在扩大。这为该领域的製药公司和研究人员提供了巨大的潜力，也为患者带来了潜在的希望。

副作用和安全问题

针对毒蕈碱乙酰胆碱受体的药物可能会引起口干、视力模糊、便秘、头晕和认知障碍等副作用。这些副作用会影响患者的依从性和生活质量，尤其是老年人群，他们可能已经因老龄化相关问题而出现这些症状。平衡治疗效果和副作用可能很困难，并且限制了患者的医嘱遵从性。还有安全性问题，因为它可能会影响心血管和呼吸系统。结果，它阻碍了市场的扩张。

标靶治疗

标靶治疗可以提供更精确的治疗选择、最大限度地减少副作用并改善治疗结果。根据每个患者的受体特征定制干预措施可以使个人化医疗成为现实，并彻底改变阿兹海默症、思觉失调症和帕金森氏症等疾病的治疗方法。此外，药物传递系统和诊断工具的进步可以优化这些治疗的功效。这为製药公司和研究人员开发创新的、以患者为中心的解决方案并推动市场成长提供了一条充满希望​​的道路。

监管障碍

开发针对毒蕈碱受体的药物需要遵守严格的监管要求，包括广泛的临床试验和安全性评估。此类要求会延长开发时间、增加成本并带来监管脱轨的风险。延误和拒绝阻碍了市场进入并阻碍了製药公司。这些障碍可能会抑制创新，延迟神经和精神疾病新治疗方法的推出，并影响市场成长和竞争。

COVID-19 的影响

COVID-19 的爆发严重影响了肌肉乙酰胆碱受体市场。由于供应链中断、研发业务受到限制以及医疗资源的重新调整，临床试验和药物开发正在推迟。此外，由于对远距医疗的重视和亲自就诊的减少，患者获得毒蕈碱受体相关药物的机会受到影响。然而，这场大流行凸显了神经学研究和创新的重要性，随着医疗保健系统适应未来的挑战和机会，也可能增加对该市场的兴趣和投资。

托吡卡胺产业预计将在预测期内成为最大的产业

预计托吡卡胺领域将占最大占有率。托吡卡胺是一种药物，属于抗胆碱能药物或毒蕈碱拮抗类药物。在眼科领域主要用作环丁二烯促效剂和散瞳剂。透过抑制虹膜和睫状肌中的毒蕈碱乙酰胆碱受体，托吡卡胺麻痹眼睛的聚焦肌肉并导致瞳孔扩张。托吡卡胺在眼科领域的应用强调了它与更大市场的联繫，该市场包括针对这些受体的药物和治疗方法，以治疗各种疾病，包括精神疾病和神经系统疾病。

预计精神疾病产业在预测期内复合年增长率最高

预计精神疾病领域在预测期内将出现良好成长。毒蕈碱乙酰胆碱受体是一组存在于中枢神经系统中的受体，在调节多种脑部功能中发挥重要作用。这些受体的功能障碍与多种精神疾病有关，包括思觉失调症、躁郁症和重度忧郁症。该市场专注于能够为精神疾病患者提供更有效、更有针对性的治疗的创新治疗方法，使其成为医疗进步的一个有前途的途径。因此，该领域的需求预计将会增加。

占有率最大的地区

由于医疗保健支出增加和老年人口增加，亚太地区在预测期内获得了最大的市场占有率。该市场包括与毒蕈碱乙酰胆碱受体（神经系统的重要组成部分）相关的药品、研究工具和诊断产品。该市场受到神经系统疾病的流行、药物开发的进步以及神经系统研究的增加等因素的影响。此外，该地区的主要製药公司、研究机构和生物技术公司正在致力于开发和商业化与这些受体相关的产品。学术界和工业界之间的合作很常见，精准医疗方法和标靶治疗是主要趋势，反映出该地区对个人化医疗解决方案的日益关注。

复合年增长率最高的地区：

由于成熟的医疗基础设施、高研发投资和大量患者人口，预计北美在预测期内将出现有益增长。市场规模受到与这些受体相关的疾病的流行、药物开发的进展以及神经病学和相关领域的研究等因素的影响。此外，製药公司正在开发针对多种医疗状况的毒蕈碱乙酰胆碱受体的药物，包括阿兹海默症神经系统疾病。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球毒蕈碱乙酰胆碱受体市场：依类型

  • 介绍
  • M1
  • M4
  • M5
  • 其他类型

第六章全球毒蕈碱乙酰胆碱受体市场：副产品

  • 介绍
  • 托吡卡胺
  • Nu-0467154
  • Anauex-273
  • 其他产品

第七章全球毒蕈碱乙酰胆碱受体市场：按配销通路

  • 介绍
  • 零售药房
  • 专卖店
  • 线上药房

第八章全球毒蕈碱乙酰胆碱受体市场：依应用分类

  • 介绍
  • 慢性阻塞性肺病
  • 阿兹海默氏症
  • 精神疾病
  • 注意力不足过动症
  • 记忆障碍

第九章全球毒蕈碱乙酰胆碱受体市场：依最终用户分类

  • 介绍
  • 製药公司
  • 医疗设施
  • 研究机构
  • 诊断中心

第十章全球毒蕈碱乙酰胆碱受体市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • AstraZeneca
  • Anavex Life Sciences Corp.
  • Sosei Heptares.
  • Karuna Therapeutics.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • NeuroHealing Pharmaceuticals Inc.
  • Heptares Therapeutics Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Johnson & Johnson
  • Boehringer Ingelheim International Gmbh
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Ltd
  • Merck & Co., Inc
  • AbbVie Inc.
  • Elsevier BV
  • Eurofins DiscoverX Corporation
  • Novus Biologicals
Product Code: SMRC24386

According to Stratistics MRC, the Global Muscarinic Acetylcholine Receptor Market is accounted for $1.75 billion in 2023 and is expected to reach $2.79 billion by 2030 growing at a CAGR of 6.9% during the forecast period. Muscarinic acetylcholine receptors are a class of receptors that can inhibit postsynaptic neurons and are involved in the regulation of several peripheral and central activities. They are responsible for regulating the parasympathetic nervous system's physiological consequences. It has both inhibitory and excitatory effects that can block or stimulate the response and is stored in the acetylcholine-producing neurons as cholinergic neurons.

According to the American Heart Association, a US-based nonprofit organization that supports medical research, the number of persons affected by Alzheimer's disease and associated dementias in the United States is expected to rise to 9.3 million by 2060.

Market Dynamics:

Driver:

Increasing prevalence of neurological disorders

Neurological conditions, such as Alzheimer's disease, Parkinson's disease, and schizophrenia, are becoming more widespread due to ageing populations and changing lifestyles. Muscarinic acetylcholine receptors play a crucial role in these disorders, making them attractive targets for drug development. Moreover, the market is growing as a result of a dire need to address the burden of neurological illnesses on healthcare systems and the growing need for innovative therapies. This presents both significant possibilities for pharmaceutical companies and researchers in the field, as well as potential hope for patients.

Restraint:

Side effects and safety concerns

Medications targeting muscarinic acetylcholine receptors can lead to adverse effects such as dry mouth, blurred vision, constipation, dizziness, and cognitive impairment. These side effects can impact patient compliance and quality of life, particularly in elderly populations that may already experience some of these symptoms due to age-related issues. Balancing therapeutic benefits with side effects is challenging, potentially limiting patient adherence. Safety concerns also arise due to the potential impact on cardiovascular and respiratory systems. Thus, they are limiting market expansion.

Opportunity:

Targeted therapies

Targeted therapies can offer more precise treatment options, minimising side effects and enhancing therapeutic outcomes. By tailoring interventions to the individual patient's receptor profile, personalised medicine becomes a reality, potentially revolutionising the treatment of conditions like Alzheimer's disease, schizophrenia, and Parkinson's disease. Furthermore, advancements in drug delivery systems and diagnostic tools can optimise the effectiveness of these therapies. This presents a promising avenue for pharmaceutical companies and researchers to develop innovative, patient-centric solutions and drive growth in the market.

Threat:

Regulatory hurdles

Developing drugs targeting muscarinic receptors requires adherence to rigorous regulatory requirements, including extensive clinical trials and safety assessments. These demands lead to extended timelines, increased costs, and the risk of regulatory setbacks. Delays or rejections can hinder market entry and deter pharmaceutical companies. These obstacles may impede innovation, potentially delaying the availability of new treatments for neurological and psychiatric disorders and impacting the market's growth and competitiveness.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the muscle acetylcholine receptor market. Clinical trial and medication development have been delayed as a result of supply chain interruptions, limitations imposed on research and development operations, and the reorganisation of healthcare resources. Additionally, patient access to muscarinic receptor-related medicines was impacted by the emphasis on telehealth and the decline in in-person healthcare visits. However, the pandemic also underscored the importance of neurological research and innovation, potentially driving increased interest and investment in this market as healthcare systems adapt to future challenges and opportunities.

The Tropicamide segment is expected to be the largest during the forecast period

The Tropicamide segment is estimated to hold the largest share. Tropicamide is a pharmaceutical medication that belongs to a class of drugs known as anticholinergics or muscarinic antagonists. In ophthalmology, it is mainly employed as a cycloplegic and mydriatic agent. Tropicamide works by paralysing the focusing muscle of the eye and dilatation of the pupil by inhibiting muscarinic acetylcholine receptors in the iris and ciliary muscle. The application of tropicamide in ophthalmology highlights its connection to the larger market, which includes medications and treatments that target these receptors to treat a range of illnesses, including psychological and neurological diseases.

The Psychiatric Disorders segment is expected to have the highest CAGR during the forecast period

The Psychiatric Disorders segment is anticipated to have lucrative growth during the forecast period. Muscarinic acetylcholine receptors are a group of receptors in the central nervous system that play a crucial role in regulating various brain functions. Dysfunction in these receptors is implicated in several psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. This segment of the market focuses on innovative therapies that can offer more effective and targeted treatments for individuals suffering from psychiatric conditions, representing a promising avenue for medical advancements. Hence, this will propel segment demand.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising healthcare expenditures and a growing geriatric population. It encompasses pharmaceuticals, research tools, and diagnostics associated with muscarinic acetylcholine receptors, vital components in the nervous system. This market is influenced by factors such as the prevalence of neurological disorders, advancing drug development, and increasing research in neurology. Moreover, major pharmaceutical companies, research institutions, and biotechnology firms in the region engage in the development and commercialization of products related to these receptors. Collaborations between academia and industry are common, and precision medicine approaches and targeted therapies are key trends, reflecting a growing focus on personalised healthcare solutions in the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the presence of a well-established healthcare infrastructure, high research and development investments, and a large patient population. The market size is influenced by factors such as the prevalence of conditions related to these receptors, advancements in drug development, and research in neurology and related fields. Furthermore, pharmaceutical companies develop drugs targeting muscarinic acetylcholine receptors for various medical conditions, including neurological disorders like Alzheimer's disease.

Key players in the market:

Some of the key players in the Muscarinic Acetylcholine Receptor Market include AstraZeneca, Anavex Life Sciences Corp., Sosei Heptares, Karuna Therapeutics, Sumitomo Dainippon Pharma Co., Ltd., NeuroHealing Pharmaceuticals Inc., Heptares Therapeutics Ltd., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Boehringer Ingelheim International Gmbh, Eli Lilly and Company, Takeda Pharmaceutical Company Ltd, Merck & Co., Inc, AbbVie Inc., Elsevier B.V., Eurofins DiscoverX Corporation and Novus Biologicals.

Key Developments:

In November 2023, AstraZeneca announces multi-year partnership with NHL and NHLPA Hockey Fights Cancer initiative. Through this multi-year partnership, AstraZeneca, the NHLPA, and the NHL will leverage the Hockey Fights Cancer platform to encourage fans to win at their own G.A.M.E: Gauge risk factors, Arrange a screening, make a donation, Educate loved ones.

In July 2023, AstraZeneca India strengthens partnership with SASTRA University. The collaboration between AstraZeneca and SASTRA University aims to strengthen industry-academia ties and equip students with expertise in various aspects of clinical research.

In June 2023, AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.

Types Covered:

  • M1
  • M4
  • M5
  • Other Types

Products Covered:

  • Tropicamide
  • Nu-0467154
  • Anauex-273
  • Other Products

Distribution Channels Covered:

  • Retail Pharmacies
  • Speciality Stores
  • Online Pharmacies

Applications Covered:

  • Chronic Obstructive Pulmonary Disease
  • Alzeheimers Disease
  • Psychiatric Disorders
  • Attention Deficit Hyperactivity Disorder
  • Memory Impairment

End Users Covered:

  • Pharmaceutical Companies
  • Healthcare Facilities
  • Research Institutes
  • Diagnostic Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Muscarinic Acetylcholine Receptor Market, By Type

  • 5.1 Introduction
  • 5.2 M1
  • 5.3 M4
  • 5.4 M5
  • 5.5 Other Types

6 Global Muscarinic Acetylcholine Receptor Market, By Product

  • 6.1 Introduction
  • 6.2 Tropicamide
  • 6.3 Nu-0467154
  • 6.4 Anauex-273
  • 6.5 Other Products

7 Global Muscarinic Acetylcholine Receptor Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Speciality Stores
  • 7.4 Online Pharmacies

8 Global Muscarinic Acetylcholine Receptor Market, By Application

  • 8.1 Introduction
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Alzeheimers Disease
  • 8.4 Psychiatric Disorders
  • 8.5 Attention Deficit Hyperactivity Disorder
  • 8.6 Memory Impairment

9 Global Muscarinic Acetylcholine Receptor Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Healthcare Facilities
  • 9.4 Research Institutes
  • 9.5 Diagnostic Centers

10 Global Muscarinic Acetylcholine Receptor Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 Anavex Life Sciences Corp.
  • 12.3 Sosei Heptares.
  • 12.4 Karuna Therapeutics.
  • 12.5 Sumitomo Dainippon Pharma Co., Ltd.
  • 12.6 NeuroHealing Pharmaceuticals Inc.
  • 12.7 Heptares Therapeutics Ltd.
  • 12.8 Pfizer Inc.
  • 12.9 GlaxoSmithKline plc
  • 12.10 Novartis AG
  • 12.11 Johnson & Johnson
  • 12.12 Boehringer Ingelheim International Gmbh
  • 12.13 Eli Lilly and Company
  • 12.14 Takeda Pharmaceutical Company Ltd
  • 12.15 Merck & Co., Inc
  • 12.16 AbbVie Inc.
  • 12.17 Elsevier B.V.
  • 12.18 Eurofins DiscoverX Corporation
  • 12.19 Novus Biologicals

List of Tables

  • Table 1 Global Muscarinic Acetylcholine Receptor Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 4 Global Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 5 Global Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 6 Global Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 8 Global Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 9 Global Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 10 Global Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 11 Global Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 12 Global Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 15 Global Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 16 Global Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 18 Global Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 19 Global Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 20 Global Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 21 Global Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 22 Global Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 24 Global Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 25 Global Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 26 Global Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 27 North America Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 29 North America Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 30 North America Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 31 North America Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 32 North America Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 33 North America Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 34 North America Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 35 North America Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 36 North America Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 37 North America Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 38 North America Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 39 North America Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 40 North America Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 41 North America Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 42 North America Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 North America Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 44 North America Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 45 North America Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 46 North America Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 47 North America Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 48 North America Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 50 North America Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 51 North America Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 52 North America Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 53 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 55 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 56 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 57 Europe Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 58 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 59 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 61 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 62 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 63 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 64 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 65 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 66 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 67 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 68 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 69 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 70 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 71 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 72 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 73 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 74 Europe Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 76 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 77 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 78 Europe Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 79 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 82 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 83 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 84 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 85 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 86 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 87 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 88 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 89 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 90 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 91 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 92 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 93 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 94 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 95 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 96 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 97 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 98 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 99 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 100 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 102 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 103 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 104 Asia Pacific Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 105 South America Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 107 South America Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 108 South America Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 109 South America Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 110 South America Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 111 South America Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 112 South America Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 113 South America Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 114 South America Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 115 South America Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 116 South America Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 117 South America Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 118 South America Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 119 South America Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 120 South America Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 121 South America Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 122 South America Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 123 South America Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 124 South America Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 125 South America Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 126 South America Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 128 South America Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 129 South America Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 130 South America Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 131 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M1 (2021-2030) ($MN)
  • Table 134 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M4 (2021-2030) ($MN)
  • Table 135 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By M5 (2021-2030) ($MN)
  • Table 136 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 137 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Product (2021-2030) ($MN)
  • Table 138 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Tropicamide (2021-2030) ($MN)
  • Table 139 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Nu-0467154 (2021-2030) ($MN)
  • Table 140 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Anauex-273 (2021-2030) ($MN)
  • Table 141 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 142 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 143 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 144 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Speciality Stores (2021-2030) ($MN)
  • Table 145 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 146 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Application (2021-2030) ($MN)
  • Table 147 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Chronic Obstructive Pulmonary Disease (2021-2030) ($MN)
  • Table 148 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Alzeheimers Disease (2021-2030) ($MN)
  • Table 149 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 150 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Attention Deficit Hyperactivity Disorder (2021-2030) ($MN)
  • Table 151 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Memory Impairment (2021-2030) ($MN)
  • Table 152 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 154 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Healthcare Facilities (2021-2030) ($MN)
  • Table 155 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 156 Middle East & Africa Muscarinic Acetylcholine Receptor Market Outlook, By Diagnostic Centers (2021-2030) ($MN)